


REMARKS

Claims 1-6 are pending.


Claims 1 and 6 have been amended to more clearly define Applicant's invention. No new matter has been added.

Rejections under 35 U.S.C. 102(b)

Claim 1 stands rejected under 35 U.S.C. 102(b) as anticipated by Janku, et al. and anticipated by Kranyushkin, et al. The references disclose the adamantane derivatives shown below.



Janku et al.



Kranyushkin et al.

The MPEP provides that a reference must teach each and every element of the claim to be anticipatory. MPEP 2131. Applicants respectfully submit that Janku et al. and Kranyushkin et al. do not teach each and every element of amended claim 1. In light of these amendments, Applicants respectfully request reconsideration and withdrawal of the 35 U.S.C. 102(b) rejections.

Objections

Dependent claims 2-6 stand objected to as depending upon a rejected claim. In response, Applicants respectfully submit that Janku et al. and Kranyushkin et al. do not anticipate amended claim 1 and, therefore, Applicants request reconsideration and withdrawal of the objection.

Respectfully submitted,

Dated: January 17, 2008

By: James T. Wasicak
James T. Wasicak
Reg. No. 50,803